Stockreport

Hemispherx Links Stanford’s ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization

HEMISPHERX BIOPHARMA  (HEB) 
NASDAQ:AMEX Investor Relations: hemispherx.net/mobile/investor-relations.php
PDF OCALA, Fla., May 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of ther [Read more]